MultiplAI Health raises £2.3m in seed funding led by SF500, Zentynel and Time Partners to advance its cardiovascular screening technology
The seed round was led by SF500, Zentynel and Time Partners to fund technical validation and US expansion.
MultiplAI Health is a techbio diagnostics firm developing universal precision screening technology for complex diseases. The company combines genomic data and artificial intelligence to create accessible blood tests for cardiovascular conditions.
MultiplAI Health has secured £2.3m in a seed funding round led by SF500, Zentynel and Time Partners. The capital will support technical validation of the company proprietary RNA based artificial intelligence product, team expansion and operations in the United States.
The firm is focused on creating a liquid biopsy test that assesses individual risk for cardiovascular disease. The fresh funds arrive as the diagnostics company looks to enter the broader American screening market and build new clinical partnerships.
From the founder
"80% of CVD-related deaths could be avoided with updated screening practices, like in cancer, where liquid biopsy is already being used to detect the disease earlier and save lives,"
Santiago Miruka
Cardiologist, Co-founder and CEO at MultiplAI Health
Investor perspective
"Since MultiplAI became one of our first startups exploring how to harness genomics applications to improve healthcare, the company has rapidly implemented its plans to consolidate its exciting technology and build an amazing team internally and externally,"
Cristián Hernández
Managing Partner, Zentynel
Use of funds
- 01Continue product development
- 02Grow the team
- 03Expand into international markets
- 04Scale operations
Investors
Categories
About the company
MultiplAI Health
MultiplAI Health develops universal precision screening technology for cardiovascular and complex diseases using genomic data and artificial intelligence.